Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma

This is an interventional treatment trial for Renal Cell Carcinoma focused on measuring collected duct carcinoma, sorafenib Read More

Inclusion Criteria:

• Age≥18 years, ≤70 years, male or female;
• Advanced collecting duct carcinoma of the kidney is diagnosed histologically or pathologically ;
• Have not received anti-angiogenesis targeted drug therapy and systemic chemotherapy;
• Have at least one measurable tumor lesion (Response Evaluation Criteria In Solid Tumors);
• Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1;
• The expected life span is ≥12 weeks;
• No contraindications for chemotherapy, with enough liver function and renal function and normal ECG recording.Peripheral hemogram: neutrophil≥1.5×109/L, Plt≥100×109/L, Hgb≥90 g/L;Renal function: serum creatinine≤1.5 folds the upper limit of normal (ULN); For patients with non-metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤2.5 ULN, For patients with metastatic liver dysfunction: alanine aminotransferase and aspartate aminotransferase≤5 ULN;
• The patients participate voluntarily and have signed the informed consent form.

Exclusion Criteria:

• Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures;
• Patients with severe acute infection without being controlled effectively or having pyogenic and chronic infections with persistently unhealed wounds;
• Past history of serious heart diseases, including: cardiac function classification ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled hypertension;
• Patients with a history of HIV infection or active phase of chronic hepatitis B/C;
• negative imaging examination result 4 weeks prior to enrollment);
• Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs);
• A history of allogeneic organ transplantation;
• Patients with evidence of hemorrhagic constitution or a past history of hemorrhage;
• Patients currently receiving renal dialysis;
• Past or present concomitant tumors with the primary lesions or histological characteristics different from the tumors evaluated in this study, excluding other tumor cured longer than 3 years before enrollment;
• Patients participating in other clinical trials simultaneously;
• Other conditions unsatisfying the inclusion criteria in the investigator's opinions.